Aura Biosciences

Yahoo Finance • 2 days ago

Aura Declares Commercial Production at Borborema

ROAD TOWN, British Virgin Islands, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aura Minerals Inc. (Nasdaq: AUGO) (B3: AURA33) (“Aura” or the “Company”) is pleased to announce that commercial production has been achieved at its Borborema gold mine... Full story

Yahoo Finance • 22 days ago

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet d... Full story

Yahoo Finance • last month

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC) Strengthened Balance Sheet with $75 Million Equity Financing; Cash Positi... Full story

Yahoo Finance • 4 months ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pric... Full story

Yahoo Finance • 6 months ago

Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential?

We recently published a list of 10 Small Cap Stocks with Huge Upside Potential. In this article, we are going to take a look at where Aura Biosciences, Inc. (NASDAQ:AURA) stands against other small cap stocks with huge upside potential. I... Full story

Yahoo Finance • 6 months ago

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment... Full story

Yahoo Finance • 6 months ago

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 C... Full story

Yahoo Finance • 7 months ago

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOS... Full story

Yahoo Finance • 7 months ago

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de... Full story

Yahoo Finance • 3 years ago

12 Stocks Insiders are Buying Now

In this article, we will look at the 12 stocks insiders are buying now. If you want to explore similar stocks, you can also take a look at 5 Stocks Insiders are Buying Now. Investing in stocks thatinsiders are buying can sometimes lead to... Full story

Yahoo Finance • 3 years ago

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate

Shares of Aura Biosciencs Inc. were up 11.3% in premarket trading on Thursday after the company said it received a Fast-Track designation from the Food and Drug Administration for its experimental bladder-cancer treatment. Aura is planning... Full story